What 11 Analyst Ratings Have To Say About Vor Biopharma
Portfolio Pulse from Benzinga Insights
In the last quarter, Vor Biopharma (NASDAQ:VOR) received 11 analyst ratings, with 6 bullish and 5 somewhat bullish. The average price target is $17.32, representing an upside from the current price of $5.08. This is a 24.7% decrease from the previous average price target of $23.00.
June 12, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vor Biopharma received 11 positive analyst ratings in the last quarter, with an average price target of $17.32, indicating potential upside from the current price of $5.08.
The 11 positive analyst ratings for Vor Biopharma suggest that the stock has potential for growth in the short term. The average price target of $17.32 is significantly higher than the current price of $5.08, indicating that analysts believe the stock is undervalued. This could lead to an increase in the stock price as investors take note of the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100